BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

ORIONPHARM

All Eps Dividend Board Agm Q1 Q2 Q3

ORIONPHARM 31-May-2020

(Q3 Un-audited): Consolidated EPS was Tk. 0.61 for January-March 2020 as against Tk. 0.95 for January-March 2019; Consolidated EPS was Tk. 2.75 for July'19-March'20 as against Tk. 3.01 for July'18-March'19. Consolidated NOCFPS was Tk. 2.73 for July'19-March'20 as against Tk. 7.15 for July'18-March'19. (cont.)

ORIONPHARM 02-May-2019

(Q3 Un-audited): Consolidated EPS was Tk. 0.95 for January-March 2019 as against Tk. 0.69 for January-March 2018; Consolidated EPS was Tk. 3.01 for July'18-March'19 as against Tk. 2.76 for July'17-March'18. Consolidated NOCFPS was Tk. 7.15 for July'18-March'19 as against Tk. 8.57 for July'17-March'18. Consolidated NAV per share (including and excluding Revaluation Surplus) was Tk. 74.29 and Tk. 66.05 respectively as on March 31, 2019 as against Tk. 72.88 and Tk. 64.55 respectively as on June 30, 2018.

ORIONPHARM 25-Apr-2019

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 30, 2019 at 5:15 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2019.

ORIONPHARM 30-Apr-2018

(Q3 Un-audited): Consolidated EPS was Tk. 0.69 for January-March 2018 as against Tk. 0.56 for Jan.-Mar. 2017; Consolidated EPS was Tk. 2.76 for July'17-March'18 as against Tk. 3.02 for July'16-March'17. Consolidated NOCFPS was Tk. 8.57 for July'17-March'18 as against Tk. 8.54 for July'16-March'17. Consolidated NAV per share (including and excluding Revaluation Surplus) was Tk. 72.07 and Tk. 63.71 respectively as on March 31, 2018 as against Tk. 70.95 and Tk. 62.48 respectively as on June 30, 2017.

ORIONPHARM 23-Apr-2018

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 28, 2018 at 5:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2018.

ORIONPHARM 02-May-2017

(Q3 Un-audited): Consolidated EPS was Tk. 0.56 for January-March 2017 as against Tk. 0.33 for January-March 2016; Consolidated EPS was Tk. 3.02 for July'16-March'17 as against Tk. 2.33 for July'15-March'16. Consolidated NOCFPS was Tk. 8.54 for July 2016-March 2017 as against Tk. 10.23 for July 2015-March 2016. Consolidated NAV per share (including and excluding Revaluation Surplus) was Tk. 71.14 and Tk. 62.63 respectively as on March 31, 2017 and Tk. 69.99 and Tk. 61.34 respectively as on June 30, 2016.

ORIONPHARM 24-Apr-2017

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 30, 2017 at 5:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2017.

ORIONPHARM 01-Nov-2015

(Q3 Un-audited): Consolidated EPS was Tk. 0.73 for July- September, 2015 as against Tk. 0.77 for July- September., 2014; Consolidated EPS was Tk. 2.88 for January-September, 2015 as against Tk. 3.80 for January-September, 2014. Consolidated NOCFPS was Tk. 5.40 for January-September, 2015 as against Tk. 8.45 for January-September, 2014. (cont.)

ORIONPHARM 25-Oct-2015

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 29, 2015 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on September 30, 2015.

ORIONPHARM 30-Oct-2014

(Q3): As per un-audited quarterly accounts for the 3rd quarter ended on 30th September 2014 (July'14 to Sep'14), the Company has reported consolidated net profit after tax (excluding non-controlling interests) of Tk. 179.34 million with consolidated EPS of Tk. 0.77 as against Tk. 229.86 million and Tk. 0.98 respectively for the same period of the previous year. Whereas consolidated net profit after tax (excluding non-controlling interests) was Tk. 888.98 million with consolidated EPS of Tk. 3.80 for the period of nine months (Jan'14 to Sep'14) ended on 30.09.2014 as against Tk. 772.17 million and Tk. 3.30 respectively for the same period of the previous year.

Previous Next page